Context Therapeutics (NASDAQ:CNTX) Given “Buy” Rating at Guggenheim

Guggenheim reaffirmed their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a research report sent to investors on Tuesday,Benzinga reports. Guggenheim currently has a $5.00 target price on the stock.

Other research analysts have also recently issued research reports about the stock. Piper Sandler upped their target price on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a research report on Tuesday. JonesTrading began coverage on Context Therapeutics in a report on Monday, December 22nd. They set a “buy” rating and a $7.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen raised Context Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Lifesci Capital upgraded Context Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.60.

Context Therapeutics Stock Performance

Shares of CNTX opened at $3.18 on Tuesday. Context Therapeutics has a 1 year low of $0.49 and a 1 year high of $3.62. The company has a market cap of $292.18 million, a price-to-earnings ratio of -8.37 and a beta of 1.96. The firm has a fifty day moving average of $2.41 and a 200-day moving average of $1.60.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Monday, March 23rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04). Analysts predict that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Trading of Context Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new stake in shares of Context Therapeutics in the 4th quarter worth approximately $43,000. Quadrature Capital Ltd acquired a new position in shares of Context Therapeutics during the fourth quarter valued at approximately $68,000. Clear Harbor Asset Management LLC increased its stake in shares of Context Therapeutics by 60.5% during the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after acquiring an additional 35,000 shares during the period. Citadel Advisors LLC bought a new stake in Context Therapeutics during the third quarter worth approximately $100,000. Finally, XTX Topco Ltd raised its holdings in Context Therapeutics by 858.8% during the fourth quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after purchasing an additional 91,008 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics News Summary

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Multiple brokerages boosted ratings and price targets — Piper Sandler raised its price target to $7 and kept an “overweight” rating, Guggenheim reaffirmed a “buy” with a $5 target, and D. Boral Capital reaffirmed a “buy” with a $9 target. These notes increase upside expectations and likely helped buying interest. Analyst Notes
• Positive Sentiment: Clinical catalysts and cash runway: Context expects Phase 1a interim data for CTIM‑76 (CLDN6 x CD3) in June 2026 and for CT‑95 (MSLN x CD3) in September 2026, with CT‑202 Phase 1 dosing planned in Q3 2026. Management reported $66.0M cash as of 12/31/25, which it says funds operations into mid‑2027 — a near‑term runway that supports continued development. Full-Year 2025 Results
• Neutral Sentiment: Company updated its corporate presentation highlighting the evolving T‑cell engager pipeline; useful for investors but not an immediate price driver by itself. Pipeline Update
• Neutral Sentiment: Short‑interest reports in late March show anomalous “0 shares / NaN” values across multiple feeds — likely a data/reporting error rather than a true change in short interest; treat these entries with caution.
• Negative Sentiment: Quarterly EPS miss: Context reported -$0.14 EPS for the quarter, missing the consensus -$0.10 estimate — a near‑term negative that can weigh on sentiment. Earnings Release / Market Reaction
• Negative Sentiment: Widening losses and lower cash vs. 2024: Net loss increased to $36.1M (from $26.7M) and cash fell to $66.0M from $94.4M a year earlier — increases R&D spend and burn risk, which could pressure the stock if upcoming data or financing plans disappoint. Financials & Milestones

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.